Freiman, J. MorganFatch, RobinCheng, DebbieEmenyonu, NnekaNgabirano, ChristineGeadas, CarolinaAdong, JulianMuyindike, Winnie R.Linas, Benjamin P.Jacobson, Karen R.Hahn, Judith A.2022-01-302022-01-302021Freiman JM, Fatch R, Cheng D, Emenyonu N, Ngabirano C, Geadas C, et al. (2021) Prevalence of elevated liver transaminases and their relationship with alcohol use in people living with HIV on anti-retroviral therapy in Uganda. PLoS ONE 16(6): e0250368. https://doi.org/10.1371/ journal.pone.0250368https://doi.org/10.1371/ journal.pone.0250368https://nru.uncst.go.ug/xmlui/handle/123456789/1639Isoniazid preventive therapy (IPT) reduces tuberculosis reactivation and mortality among persons living with HIV (PLWH), yet hepatotoxicity concerns exclude “regular and heavy alcohol drinkers” from IPT. We aimed to determine the prevalence of elevated liver transaminases among PLWH on antiretroviral therapy (ART) who engage in alcohol use. The Immune Suppression Syndrome Clinic of Mbarara, Uganda. We defined elevated liver transaminases as 1.25 times (X) the upper limit of normal (ULN) for alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST). We evaluated the associations of current alcohol use and other variables of interest (sex, body mass index, and ART regimen) with elevated transaminases at study screening, using multivariable logistic regression to obtain adjusted odds ratios (aOR) and 95% confidence intervals (CI)enLiver transaminasesAlcohol usePeople living with HIVAnti-retroviral therapyUgandaArticle